const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE"; // 13.3" x 7.5"
pres.title = "Emergency Drugs Quick Reference";
pres.author = "Emergency Medicine Reference";

// ============================================================
// COLOUR PALETTE
// Deep navy dominant, teal accent, amber highlight, white text
// ============================================================
const C = {
  navy:      "0B1F3A",
  navyMid:   "122747",
  teal:      "0D8A8A",
  tealLight: "14AAAA",
  amber:     "F5A623",
  amberDark: "D4891E",
  red:       "C0392B",
  green:     "1A9B5F",
  purple:    "6C3FA0",
  gray:      "ECF0F1",
  white:     "FFFFFF",
  textDark:  "1A1A2E",
  badge_ci:  "C0392B",
  badge_ind: "1A9B5F",
  badge_mech:"1565C0",
};

// ============================================================
// DRUG DATA
// ============================================================
const drugs = [
  {
    name: "LABETALOL",
    category: "Antihypertensive",
    color: C.teal,
    mechanism: "Combined α1 + β1/β2 adrenergic blocker → reduces peripheral vascular resistance + heart rate without reflex tachycardia",
    indications: ["Hypertensive emergency", "Hypertension in pregnancy (pre-eclampsia)", "Aortic dissection", "Acute ischemic stroke (BP >185/110)", "Cocaine-induced hypertension"],
    contraindications: ["Asthma/COPD (bronchospasm)", "Decompensated heart failure", "Bradycardia / Heart block (2nd/3rd degree)", "Cardiogenic shock", "Hypotension"],
    dilution: "50 mg in 40 mL NS = 1 mg/mL; OR undiluted bolus 5–10 mg IV push",
    dose: "IV Bolus: 20 mg slow IV over 2 min, repeat 40–80 mg q10min\nInfusion: 1–2 mg/min",
    maxDose: "300 mg total (bolus) or 300 mg cumulative dose",
    halfLife: "5–8 hours",
    shelfLife: "Vial: 3 years; Diluted: 24 h at room temp",
    notes: "Monitor BP every 5 min. Onset 2–5 min IV.",
  },
  {
    name: "METOCLOPRAMIDE",
    category: "Antiemetic / Prokinetic",
    color: C.green,
    mechanism: "D2 dopamine receptor antagonist (central & peripheral) + 5-HT4 agonist → accelerates gastric emptying, blocks CTZ vomiting centre",
    indications: ["Nausea/vomiting (post-op, chemo, migraine)", "Diabetic gastroparesis", "GERD adjunct", "Facilitate small bowel intubation", "Migraine headache (adjunct)"],
    contraindications: ["GI obstruction / perforation", "Pheochromocytoma", "Seizure disorders (lowers threshold)", "Parkinson's disease", "Tardive dyskinesia history", "Methemoglobinemia (G6PD deficiency)"],
    dilution: "10 mg in 50–100 mL NS, infuse over 15–30 min (slow IV reduces akathisia)",
    dose: "10 mg IV/IM q6–8h; 10–15 mg oral TDS",
    maxDose: "40 mg/day (IV); 60 mg/day (oral)",
    halfLife: "5–6 hours",
    shelfLife: "Ampule: 3 years; Diluted: 24–48 h (2–8°C)",
    notes: "Risk of extrapyramidal effects (EPS). Use diphenhydramine prophylaxis in high-risk patients.",
  },
  {
    name: "TRAMADOL",
    category: "Opioid Analgesic",
    color: C.purple,
    mechanism: "Weak μ-opioid receptor agonist + inhibits reuptake of serotonin & norepinephrine → dual analgesic mechanism",
    indications: ["Moderate-to-severe pain", "Post-operative analgesia", "Neuropathic pain", "Chronic pain management", "Musculoskeletal pain"],
    contraindications: ["Epilepsy / seizure disorder", "MAO inhibitor use (risk of serotonin syndrome)", "Severe hepatic/renal impairment", "Acute alcohol intoxication", "Respiratory depression", "Children <12 years"],
    dilution: "50–100 mg in 100 mL NS, infuse over 30–60 min; avoid rapid bolus",
    dose: "50–100 mg IV/IM/oral q4–6h",
    maxDose: "400 mg/day (adults); 300 mg/day (elderly or renal impairment)",
    halfLife: "6 hours (parent); 7–9 hours (active metabolite O-desmethyltramadol)",
    shelfLife: "Ampule: 3 years; Diluted: 24 h",
    notes: "Seizure risk; avoid in serotonin syndrome. Tramadol ≠ Tapentadol (different profiles).",
  },
  {
    name: "TAPENTADOL",
    category: "Opioid Analgesic (Dual MOA)",
    color: "5E3A8C",
    mechanism: "μ-opioid receptor agonist + norepinephrine reuptake inhibitor (NRI) → strong analgesic with less serotonergic activity than tramadol",
    indications: ["Moderate-to-severe acute pain", "Chronic nociceptive & neuropathic pain", "Diabetic peripheral neuropathy", "Post-operative pain"],
    contraindications: ["MAO inhibitors (within 14 days)", "Severe respiratory depression", "Paralytic ileus", "Acute intoxication", "Uncontrolled epilepsy", "Children <18 years"],
    dilution: "Oral tablets only (50, 75, 100 mg); No IV formulation available",
    dose: "50–100 mg oral q4–6h; Day 1 max: second dose 1h after first if needed",
    maxDose: "600 mg/day (Day 1); 500 mg/day (Day 2 onwards)",
    halfLife: "4 hours",
    shelfLife: "Tablets: 2–3 years (room temperature, dry)",
    notes: "Less constipation & nausea than tramadol. Titrate carefully in hepatic impairment.",
  },
  {
    name: "AVIL (PHENIRAMINE)",
    category: "Antihistamine (H1 blocker)",
    color: "2E86AB",
    mechanism: "Competitive H1-receptor antagonist → blocks histamine action on blood vessels, bronchi, GI tract + anticholinergic + mild CNS sedation",
    indications: ["Allergic reactions / Anaphylaxis (adjunct)", "Urticaria & angioedema", "Drug hypersensitivity reactions", "Pruritus", "Transfusion reactions", "Rhinitis", "Insect bite reactions"],
    contraindications: ["Narrow-angle glaucoma", "Prostatic hypertrophy (urinary retention)", "Severe hepatic disease", "MAO inhibitor use", "Neonates/premature infants"],
    dilution: "22.75 mg (1 mL ampule) diluted in 10–20 mL NS, slow IV over 5–10 min; or undiluted IM",
    dose: "22.75–45.5 mg IM/slow IV; 4 mg oral TDS",
    maxDose: "100 mg/day",
    halfLife: "16–19 hours",
    shelfLife: "Ampule: 3 years; Diluted: use immediately",
    notes: "NOT a substitute for epinephrine in anaphylaxis — epinephrine is first-line. Causes drowsiness.",
  },
  {
    name: "TRANEXAMIC ACID (TXA)",
    category: "Antifibrinolytic / Hemostatic",
    color: C.red,
    mechanism: "Synthetic lysine analogue → competitively inhibits plasminogen activation to plasmin → prevents fibrin clot degradation → reduces bleeding",
    indications: ["Trauma with major hemorrhage (within 3 hours)", "Postpartum hemorrhage (PPH)", "Surgical hemorrhage (cardiac, ortho, GI)", "Hemophilia with bleeds", "Epistaxis (topical/IV)", "Heavy menstrual bleeding"],
    contraindications: ["Active thromboembolic disease (DVT, PE, stroke)", "Subarachnoid hemorrhage (risk vasospasm)", "Hematuria from upper urinary tract (clot retention)", "DIC with fibrinolytic state being protective", "Allergy to TXA"],
    dilution: "1 g in 100 mL NS or D5W, infuse over 10 min (loading); then 1 g over 8 hours (maintenance)\nDO NOT mix with blood products",
    dose: "Loading: 1 g IV over 10 min → Maintenance: 1 g IV over 8 h\nPPH: 1 g IV, repeat 30 min later if needed",
    maxDose: "2–3 g/day (most protocols)",
    halfLife: "2–3 hours",
    shelfLife: "Ampule: 5 years; Diluted: 24 h (refrigerated)",
    notes: "CRASH-2 trial: reduces mortality in trauma if given <3h of injury. Ineffective if given >3h.",
  },
  {
    name: "PHENYTOIN",
    category: "Antiepileptic / Antiarrhythmic",
    color: "7F5AF0",
    mechanism: "Blocks voltage-gated Na⁺ channels → stabilizes neuronal membranes → reduces repetitive firing; also class Ib antiarrhythmic action",
    indications: ["Status epilepticus (second-line after benzodiazepines)", "Generalised tonic-clonic seizures (maintenance)", "Trigeminal neuralgia", "Ventricular arrhythmias (digoxin-induced)", "Traumatic brain injury seizure prophylaxis"],
    contraindications: ["Sinus bradycardia / SA/AV block (2nd or 3rd degree)", "Adams-Stokes syndrome", "Porphyria", "Pregnancy (teratogenic – fetal hydantoin syndrome)", "Hypotension"],
    dilution: "Dilute in NS ONLY (precipitates in dextrose). Max 6.7 mg/mL (250 mg in 40 mL NS)\nDO NOT refrigerate diluted solution",
    dose: "Loading: 15–20 mg/kg IV at ≤50 mg/min (≤25 mg/min elderly/cardiac)\nMaintenance: 100 mg IV/oral q8h",
    maxDose: "Loading: 1500 mg total; Maintenance: 600 mg/day",
    halfLife: "22 hours (dose-dependent / non-linear kinetics – zero order at high doses)",
    shelfLife: "Vial: 3–5 years; Diluted in NS: USE WITHIN 4 HOURS (precipitates easily)",
    notes: "Monitor ECG and BP during infusion. Therapeutic range: 10–20 mcg/mL. Purple glove syndrome with peripheral IV extravasation.",
  },
  {
    name: "LORAZEPAM",
    category: "Benzodiazepine / Anxiolytic",
    color: "0F7173",
    mechanism: "Enhances GABA-A receptor Cl⁻ influx → CNS depression → anticonvulsant, anxiolytic, sedative, muscle relaxant, amnesic effects",
    indications: ["Status epilepticus (FIRST-LINE)", "Acute anxiety / panic attacks", "Alcohol withdrawal seizures", "Pre-procedure sedation", "Acute agitation", "Procedural amnesia"],
    contraindications: ["Severe respiratory depression", "Acute angle-closure glaucoma", "Myasthenia gravis", "Alcohol or CNS depressant intoxication (relative)", "Neonates with neonatal jaundice (benzyl alcohol)"],
    dilution: "Undiluted IM; IV: dilute 1:1 with NS, D5W or sterile water; infuse at max 2 mg/min",
    dose: "Status epilepticus: 0.1 mg/kg IV (max 4 mg/dose), repeat once in 5–10 min\nAnxiety/sedation: 1–4 mg IV/IM q4–8h",
    maxDose: "8 mg/episode (seizure); 10 mg/day routine use",
    halfLife: "10–20 hours (no active metabolites – advantage in hepatic disease)",
    shelfLife: "Vial: 2 years (refrigerate 2–8°C); stable 8 weeks at room temp; Diluted: use within 4 h",
    notes: "Unlike diazepam: no active metabolites, shorter duration, less respiratory depression. Keep flumazenil reversal agent available.",
  },
  {
    name: "ONDANSETRON",
    category: "Antiemetic (5-HT3 Antagonist)",
    color: "2D6A4F",
    mechanism: "Selective 5-HT3 (serotonin) receptor antagonist → blocks vagal afferents in GI tract + chemoreceptor trigger zone (CTZ) in brainstem → antiemetic",
    indications: ["Chemotherapy-induced nausea/vomiting (CINV)", "Post-operative nausea/vomiting (PONV)", "Radiation-induced nausea", "Gastroenteritis", "Migraine-associated vomiting", "Nausea in pregnancy (severe)"],
    contraindications: ["QT prolongation / Long QT syndrome", "Congenital QT syndrome", "Hypokalemia/hypomagnesemia (risk of torsades)", "Serotonin syndrome (with serotonergic drugs)", "Concurrent apomorphine use (hypotension)"],
    dilution: "4 mg in 50 mL NS or D5W, infuse over 15–30 min; OR 4 mg undiluted slow IV over ≥30 sec",
    dose: "4–8 mg IV/IM q4–8h; CINV: 8–32 mg IV (depending on emetogenicity)",
    maxDose: "32 mg/day IV (CINV); 16 mg/day (routine antiemesis)",
    halfLife: "3–6 hours",
    shelfLife: "Vial: 3 years; Diluted: 24 h (2–30°C); protect from light",
    notes: "Avoid rapid IV push – risk of QT prolongation. Obtain ECG if QTc >450 ms. Headache is common side effect.",
  },
  {
    name: "NORADRENALINE (NOREPINEPHRINE)",
    category: "Vasopressor / Catecholamine",
    color: "B03A2E",
    mechanism: "Potent α1 agonist (vasoconstriction ↑SVR) + moderate β1 agonist (↑HR/contractility) → raises MAP, minimal β2 effect → vasoconstriction predominates",
    indications: ["Septic shock (FIRST-LINE vasopressor)", "Cardiogenic shock (adjunct)", "Distributive shock", "Vasodilatory shock post-cardiac surgery", "Neurogenic shock"],
    contraindications: ["Hypovolemic shock (without adequate fluid replacement)", "Mesenteric/peripheral vascular thrombosis", "Halothane/cyclopropane anesthesia (arrhythmias)", "Hypersensitivity to bisulfites"],
    dilution: "Standard: 4 mg (4 mL) in 250 mL NS/D5W = 16 mcg/mL\nDouble concentration: 8 mg in 250 mL = 32 mcg/mL\nCentral line STRONGLY preferred",
    dose: "Start: 0.01–0.1 mcg/kg/min IV infusion; Titrate to MAP ≥65 mmHg",
    maxDose: "3.3 mcg/kg/min (doses >0.5 mcg/kg/min signal severe shock)",
    halfLife: "2.5 minutes (eliminated rapidly by COMT/MAO)",
    shelfLife: "Ampule: 3 years; Diluted: 24 h protected from light; Discard if discoloration",
    notes: "USE CENTRAL LINE if possible. Peripheral extravasation causes tissue necrosis – treat with phentolamine. Monitor BP continuously.",
  },
  {
    name: "ADRENALINE (EPINEPHRINE)",
    category: "Vasopressor / Bronchodilator / Cardiac",
    color: "C0392B",
    mechanism: "α1 + α2 + β1 + β2 agonist → vasoconstriction (α), ↑HR/contractility (β1), bronchodilation (β2), mast cell stabilization → reverses anaphylaxis",
    indications: ["Anaphylaxis / Severe allergic reaction (FIRST-LINE)", "Cardiac arrest (VF/pVT/asystole/PEA)", "Severe bronchospasm / Status asthmaticus", "Croup (nebulized)", "Bradycardia (refractory)", "Local anesthetic adjunct"],
    contraindications: ["No absolute contraindication in anaphylaxis or cardiac arrest", "Relative: Hypertrophic cardiomyopathy (outflow obstruction)", "Narrow-angle glaucoma (if topical)", "Cocaine/halogenated anesthetic arrhythmia risk"],
    dilution: "Anaphylaxis IM: undiluted 1:1000 (1 mg/mL) → 0.3–0.5 mg IM thigh\nCardiac arrest IV: 1:10,000 (0.1 mg/mL) = 1 mg in 10 mL NS\nInfusion: 1 mg in 250 mL NS = 4 mcg/mL",
    dose: "Anaphylaxis: 0.3–0.5 mg IM (1:1000), repeat q5–15 min\nCardiac arrest: 1 mg IV q3–5 min\nInfusion: 0.01–1 mcg/kg/min",
    maxDose: "No fixed maximum in arrest; Anaphylaxis: repeat IM as needed",
    halfLife: "2–3 minutes (IV)",
    shelfLife: "Ampule: 3 years; protect from light/heat; discard if brown/precipitate",
    notes: "NEVER give 1:1000 IV directly (cardiac arrest). Concentration confusion is a common error. Autoinjectors (EpiPen): 0.3 mg adult.",
  },
  {
    name: "DOBUTAMINE",
    category: "Inotrope / Catecholamine",
    color: "1565C0",
    mechanism: "Primarily β1 agonist (↑contractility + ↑HR) + mild β2 (slight vasodilation) → ↑cardiac output, ↓afterload, ↓PCWP; minimal α effect → less vasoconstriction than dopamine",
    indications: ["Acute decompensated heart failure", "Cardiogenic shock (with adequate BP)", "Low cardiac output states", "Cardiac stress testing (pharmacological)", "Post-cardiac surgery low output syndrome"],
    contraindications: ["HOCM / Dynamic LVOT obstruction", "Uncorrected hypovolemia", "Idiopathic hypertrophic subaortic stenosis", "Pheochromocytoma", "Atrial fibrillation (may increase ventricular response)"],
    dilution: "250 mg in 250 mL NS/D5W = 1000 mcg/mL\nStandard: 250 mg in 500 mL = 500 mcg/mL\nTitrate by weight (mcg/kg/min)",
    dose: "2.5–10 mcg/kg/min IV infusion; Start low, titrate up",
    maxDose: "40 mcg/kg/min (rarely needed >20 mcg/kg/min)",
    halfLife: "2 minutes",
    shelfLife: "Vial: 3 years; Diluted: 24 h room temp (may turn pink – still potent)",
    notes: "Pink discoloration of diluted solution is acceptable. Tolerance develops within 72 h. Often combined with noradrenaline in cardiogenic shock.",
  },
  {
    name: "DOPAMINE",
    category: "Vasopressor / Inotrope / Catecholamine",
    color: "6C3FA0",
    mechanism: "Dose-dependent receptor action:\n• 1–5 mcg/kg/min: DA1 → renal/mesenteric vasodilation\n• 5–10: β1 → ↑HR, ↑contractility\n• >10: α1 → vasoconstriction (like noradrenaline)",
    indications: ["Cardiogenic shock", "Septic shock (second-line to noradrenaline)", "Hemodynamically significant bradycardia (low-to-mid dose)", "Acute decompensated heart failure", "Neonatal hypotension"],
    contraindications: ["Tachyarrhythmias (VF, VT)", "Uncorrected hypovolemia", "Pheochromocytoma", "Sulfite allergy (formulation contains sodium metabisulfite)", "MAOI therapy (hypertensive crisis)"],
    dilution: "200–400 mg in 250 mL NS/D5W\nStandard 1600 mcg/mL: 400 mg in 250 mL",
    dose: "Start 5 mcg/kg/min; titrate to effect\nLow: 1–5 | Medium: 5–10 | High: >10 mcg/kg/min",
    maxDose: "50 mcg/kg/min",
    halfLife: "2 minutes",
    shelfLife: "Vial: 3 years; Diluted: 24 h; Discard if discolored",
    notes: "'Renal dose' dopamine (1–3 mcg/kg/min) for renal protection is NOT evidence-based. Second-line to noradrenaline in septic shock (more arrhythmias).",
  },
  {
    name: "ATROPINE",
    category: "Anticholinergic / Vagolytic",
    color: "D35400",
    mechanism: "Competitive muscarinic acetylcholine receptor antagonist → blocks parasympathetic (vagal) tone → ↑HR, ↓secretions, bronchodilation, ↓GI motility, mydriasis",
    indications: ["Symptomatic bradycardia (sinus, AVB)", "Cardiac arrest with asystole/PEA bradycardia", "Organophosphate / nerve agent poisoning", "Pre-medication (↓secretions before intubation)", "Reversal of NMB (with neostigmine)", "Beta-blocker/CCB overdose (adjunct)"],
    contraindications: ["Narrow-angle glaucoma", "Tachycardia (>100 bpm)", "Urinary retention / BPH", "Thyrotoxicosis", "Myasthenia gravis", "Acute MI with sinus tachycardia"],
    dilution: "May be given undiluted IV push; for organophosphate: large doses diluted in NS\nIntubation pre-med: 0.01 mg/kg undiluted",
    dose: "Bradycardia: 0.5–1 mg IV q3–5 min\nOrganophosphate: 1–4 mg IV q5–10 min (titrate until secretions dry)\nChildren: 0.02 mg/kg (min 0.1 mg)",
    maxDose: "3 mg (bradycardia); Organophosphate: NO maximum – titrate to effect (may need hundreds of mg)",
    halfLife: "2–5 hours",
    shelfLife: "Ampule: 3–5 years; Diluted: use within 24 h",
    notes: "Doses <0.5 mg may cause paradoxical bradycardia (central vagal stimulation). In organophosphate poisoning, titrate to drying of secretions, NOT to heart rate.",
  },
  {
    name: "NITROGLYCERIN (GTN)",
    category: "Nitrate / Vasodilator",
    color: "0D8A8A",
    mechanism: "Converted to nitric oxide (NO) → activates guanylyl cyclase → ↑cGMP → smooth muscle relaxation → venodilation (↓preload) > arteriodilation (↓afterload) at high doses → ↓myocardial O₂ demand",
    indications: ["Acute coronary syndrome (ACS/NSTEMI/STEMI)", "Unstable angina", "Acute pulmonary edema (↓preload)", "Hypertensive emergency with ACS/LVF", "Esophageal spasm", "Anal fissure (topical)"],
    contraindications: ["Hypotension (SBP <90 mmHg)", "PDE-5 inhibitors (sildenafil, tadalafil – severe hypotension ≥24h)", "Right ventricular infarction / RV failure", "Hypertrophic cardiomyopathy", "Raised ICP", "Severe aortic stenosis"],
    dilution: "Infusion: 50 mg in 250 mL D5W (GLASS bottle) = 200 mcg/mL\nAvoid PVC tubing (adsorption – use polyethylene/glass sets)\nSublingual: 0.3–0.6 mg tablet or spray",
    dose: "Sublingual: 0.3–0.6 mg q5 min × 3 doses\nIV infusion: Start 5–10 mcg/min, titrate by 5–10 mcg/min q3–5 min",
    maxDose: "IV: 400 mcg/min (200–400 mcg/min range)",
    halfLife: "1–4 minutes (IV); ~10 min sublingual",
    shelfLife: "Tablets: 6 months after opening (store in original glass container). IV vials: 2–3 years; Diluted: 24 h in glass",
    notes: "Tolerance develops within 24 h continuous use – use nitrate-free interval 8–12 h. Headache very common (N.O. vasodilation). Adsorbs to PVC – always use non-PVC tubing.",
  },
  {
    name: "IV FLUIDS",
    category: "Volume Expander / Resuscitation",
    color: "3498DB",
    mechanism: "• 0.9% NaCl / Hartmann's: Expand intravascular volume → ↑preload → ↑cardiac output per Frank-Starling\n• Colloids (albumin, gelatin): Higher molecular weight → remain in intravascular compartment longer\n• D5W/D10W: Free water distribution – only 1/12 stays intravascular → NOT for resuscitation",
    indications: [
      "0.9% NaCl: Hypovolemic shock, metabolic alkalosis, hyperkalemia resuscitation, drug dilution, normal saline challenge",
      "Hartmann's/LR: Trauma, surgical losses, burns, general resuscitation (more physiological – less hyperchloremic acidosis)",
      "D5W: Hypernatremia correction, maintenance, drug dilution",
      "D10W / D50W: Hypoglycemia treatment",
      "Albumin 4–5%: Septic shock (after initial crystalloid), cirrhosis SBP",
      "Plasma expanders: Massive blood loss bridging"
    ],
    contraindications: [
      "0.9% NaCl: Large volumes → hyperchloremic metabolic acidosis; avoid in TBI (raises ICP vs isotonic solutions)",
      "Hartmann's/LR: Avoid in hyperkalemia",
      "Dextrose solutions: Avoid in head injury/stroke (hyperglycemia worsens outcomes), pulmonary edema",
      "Colloids (HES/Gelofusin): Avoid in renal failure/coagulopathy"
    ],
    dilution: "Given as packaged; typical rates:\nResuscitation bolus: 500 mL–1 L over 15–30 min\nMaintenance: 1–2 mL/kg/h\nBlood product: follow massive transfusion protocol",
    dose: "Resuscitation: 20 mL/kg bolus (repeat to reassess)\nFluid challenge: 250–500 mL over 10–15 min\nAdult maintenance: 25–30 mL/kg/day",
    maxDose: "No fixed maximum – guided by clinical response, avoid fluid overload",
    halfLife: "Crystalloids: ~20–30 min intravascular retention\nColloids: 3–6 hours\nAlbumin: 12–16 hours",
    shelfLife: "Unopened bags: 2–5 years; Once opened: USE WITHIN 24 h; Discard if turbid/particulate",
    notes: "Reassess after each bolus. RASS/CVP/echocardiography-guided fluid therapy. Avoid excessive fluid – ARDS and AKI risk.",
  },
];

// ============================================================
// HELPER: Create individual drug card slide
// ============================================================
function addCoverSlide(pres) {
  const slide = pres.addSlide();
  // Background
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 13.3, h: 7.5,
    fill: { color: C.navy }, line: { type: "none" }
  });
  // Red accent bar
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 6.7, w: 13.3, h: 0.8,
    fill: { color: C.red }, line: { type: "none" }
  });
  // Teal accent stripe
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 0.12, h: 7.5,
    fill: { color: C.teal }, line: { type: "none" }
  });
  // Title
  slide.addText("EMERGENCY DRUGS", {
    x: 0.5, y: 1.5, w: 12.3, h: 1.2,
    fontSize: 54, fontFace: "Arial", bold: true,
    color: C.white, align: "center", charSpacing: 8, margin: 0
  });
  slide.addText("QUICK REFERENCE CHART", {
    x: 0.5, y: 2.8, w: 12.3, h: 0.7,
    fontSize: 26, fontFace: "Arial", bold: false,
    color: C.tealLight, align: "center", charSpacing: 4, margin: 0
  });
  // Subtitle line
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 4, y: 3.6, w: 5.3, h: 0.04,
    fill: { color: C.amber }, line: { type: "none" }
  });
  slide.addText("Mechanism  •  Indications  •  Contraindications  •  Dose & Dilution\nMax Dose  •  Half-life  •  Shelf Life", {
    x: 0.5, y: 3.8, w: 12.3, h: 1.2,
    fontSize: 16, fontFace: "Arial",
    color: C.gray, align: "center", margin: 0
  });
  slide.addText("16 Essential Emergency Medications", {
    x: 0.5, y: 5.2, w: 12.3, h: 0.5,
    fontSize: 14, fontFace: "Arial", italic: true,
    color: C.amber, align: "center", margin: 0
  });
  slide.addText("For Healthcare Professionals • Clinical Use Reference", {
    x: 0.5, y: 6.8, w: 12.3, h: 0.4,
    fontSize: 11, fontFace: "Arial",
    color: C.white, align: "center", margin: 0
  });
}

function addDrugSlide(pres, drug) {
  const slide = pres.addSlide();
  const W = 13.3, H = 7.5;
  const col = drug.color;

  // --- BACKGROUND ---
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: W, h: H,
    fill: { color: "F7F9FC" }, line: { type: "none" }
  });

  // --- HEADER BAR ---
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: W, h: 1.15,
    fill: { color: col }, line: { type: "none" }
  });
  // Dark navy overlay at right side for category badge
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 9.5, y: 0, w: 3.8, h: 1.15,
    fill: { color: C.navy }, line: { type: "none" }
  });

  // Drug name
  slide.addText(drug.name, {
    x: 0.2, y: 0.05, w: 9.2, h: 0.65,
    fontSize: 30, fontFace: "Arial", bold: true,
    color: C.white, margin: 0
  });
  // Category badge
  slide.addText(drug.category, {
    x: 9.5, y: 0.0, w: 3.8, h: 1.15,
    fontSize: 11, fontFace: "Arial", bold: true,
    color: C.amber, align: "center", valign: "middle", margin: 4
  });

  // ---- LAYOUT: 3-column grid below header ----
  // Col widths: 4.3 | 4.3 | 4.3 (with 0.1 gutters), start y=1.25
  const rowTop = 1.25;
  const rowH = 5.9;
  const cW = 4.25;
  const gutter = 0.1;
  const col1x = 0.1, col2x = col1x + cW + gutter, col3x = col2x + cW + gutter;

  // Card backgrounds
  [col1x, col2x, col3x].forEach(cx => {
    slide.addShape(pres.shapes.RECTANGLE, {
      x: cx, y: rowTop, w: cW, h: rowH,
      fill: { color: C.white },
      line: { color: "D0D8E4", pt: 1 },
      shadow: { type: "outer", color: "B0B8C8", blur: 4, offset: 2, angle: 135, opacity: 0.12 }
    });
  });

  // Colored accent top bar on each card
  [col1x, col2x, col3x].forEach(cx => {
    slide.addShape(pres.shapes.RECTANGLE, {
      x: cx, y: rowTop, w: cW, h: 0.07,
      fill: { color: col }, line: { type: "none" }
    });
  });

  const SEC_LABEL_H = 0.28;
  const SEC_LABEL_FS = 9;
  const SEC_BODY_FS = 9.5;
  const padding = 0.12;

  // ========== COLUMN 1: MECHANISM + DOSE + DILUTION ==========
  let y1 = rowTop + 0.15;

  // MECHANISM
  slide.addText("⚙ MECHANISM", {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: col, margin: 0
  });
  y1 += SEC_LABEL_H + 0.02;
  slide.addText(drug.mechanism, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: 1.1,
    fontSize: SEC_BODY_FS - 0.5, fontFace: "Arial",
    color: C.textDark, margin: 0, wrap: true
  });
  y1 += 1.15;

  // divider
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: 0.015,
    fill: { color: "D0D8E4" }, line: { type: "none" }
  });
  y1 += 0.07;

  // DOSE
  slide.addText("💊 DOSE", {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: col, margin: 0
  });
  y1 += SEC_LABEL_H + 0.02;
  slide.addText(drug.dose, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: 0.85,
    fontSize: SEC_BODY_FS - 0.5, fontFace: "Arial",
    color: C.textDark, margin: 0, wrap: true
  });
  y1 += 0.9;

  // MAX DOSE badge
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: 0.36,
    fill: { color: C.amber }, line: { type: "none" }
  });
  slide.addText("MAX: " + drug.maxDose, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: 0.36,
    fontSize: 8.5, fontFace: "Arial", bold: true,
    color: C.navy, align: "center", valign: "middle", margin: 0
  });
  y1 += 0.42;

  // divider
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: 0.015,
    fill: { color: "D0D8E4" }, line: { type: "none" }
  });
  y1 += 0.07;

  // DILUTION
  slide.addText("🧪 HOW TO DILUTE", {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: col, margin: 0
  });
  y1 += SEC_LABEL_H + 0.02;
  const dilutionH = rowTop + rowH - y1 - 0.15;
  slide.addText(drug.dilution, {
    x: col1x + padding, y: y1, w: cW - 2*padding, h: dilutionH,
    fontSize: SEC_BODY_FS - 0.5, fontFace: "Arial",
    color: C.textDark, margin: 0, wrap: true
  });

  // ========== COLUMN 2: INDICATIONS + CONTRAINDICATIONS ==========
  let y2 = rowTop + 0.15;

  // INDICATIONS
  slide.addText("✅ INDICATIONS", {
    x: col2x + padding, y: y2, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: C.green, margin: 0
  });
  y2 += SEC_LABEL_H + 0.04;
  const indItems = Array.isArray(drug.indications) ? drug.indications : [drug.indications];
  const indText = indItems.map(i => ({ text: i, options: { bullet: { code: "2022" }, breakLine: true, fontSize: SEC_BODY_FS - 0.5 } }));
  const indH = Math.min(2.6, indItems.length * 0.38);
  slide.addText(indText, {
    x: col2x + padding, y: y2, w: cW - 2*padding, h: indH,
    fontSize: SEC_BODY_FS - 0.5, fontFace: "Arial",
    color: C.textDark, margin: 0, paraSpaceAfter: 1
  });
  y2 += indH + 0.08;

  // divider
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col2x + padding, y: y2, w: cW - 2*padding, h: 0.015,
    fill: { color: "D0D8E4" }, line: { type: "none" }
  });
  y2 += 0.07;

  // CONTRAINDICATIONS
  slide.addText("🚫 CONTRAINDICATIONS", {
    x: col2x + padding, y: y2, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: C.red, margin: 0
  });
  y2 += SEC_LABEL_H + 0.04;
  const ciItems = Array.isArray(drug.contraindications) ? drug.contraindications : [drug.contraindications];
  const ciText = ciItems.map(i => ({ text: i, options: { bullet: { code: "2022" }, breakLine: true, fontSize: SEC_BODY_FS - 1 } }));
  const ciH = rowTop + rowH - y2 - 0.12;
  slide.addText(ciText, {
    x: col2x + padding, y: y2, w: cW - 2*padding, h: ciH,
    fontSize: SEC_BODY_FS - 1, fontFace: "Arial",
    color: C.textDark, margin: 0, paraSpaceAfter: 1
  });

  // ========== COLUMN 3: HALF-LIFE + SHELF-LIFE + NOTES ==========
  let y3 = rowTop + 0.15;

  // Half-life pill
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col3x + padding, y: y3, w: (cW - 2*padding) / 2 - 0.05, h: 0.7,
    fill: { color: "EEF4FF" }, line: { color: "AABBD4", pt: 1 }
  });
  slide.addText([
    { text: "HALF-LIFE\n", options: { bold: true, fontSize: 7.5, color: C.navy } },
    { text: drug.halfLife, options: { fontSize: 8.5, color: col, bold: true } }
  ], {
    x: col3x + padding, y: y3, w: (cW - 2*padding) / 2 - 0.05, h: 0.7,
    align: "center", valign: "middle", margin: 2
  });

  slide.addShape(pres.shapes.RECTANGLE, {
    x: col3x + (cW)/2 + 0.05, y: y3, w: (cW - 2*padding) / 2 - 0.05, h: 0.7,
    fill: { color: "FFF9EE" }, line: { color: "E8D4A0", pt: 1 }
  });
  slide.addText([
    { text: "SHELF LIFE\n", options: { bold: true, fontSize: 7.5, color: C.navy } },
    { text: drug.shelfLife.split(";")[0], options: { fontSize: 7.5, color: C.amberDark, bold: true } }
  ], {
    x: col3x + (cW)/2 + 0.05, y: y3, w: (cW - 2*padding) / 2 - 0.05, h: 0.7,
    align: "center", valign: "middle", margin: 2
  });

  y3 += 0.8;

  // SHELF LIFE detail
  slide.addText("📦 SHELF / STORAGE", {
    x: col3x + padding, y: y3, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: C.amberDark, margin: 0
  });
  y3 += SEC_LABEL_H + 0.02;
  slide.addText(drug.shelfLife, {
    x: col3x + padding, y: y3, w: cW - 2*padding, h: 0.7,
    fontSize: SEC_BODY_FS - 1.5, fontFace: "Arial",
    color: C.textDark, margin: 0, wrap: true
  });
  y3 += 0.75;

  // divider
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col3x + padding, y: y3, w: cW - 2*padding, h: 0.015,
    fill: { color: "D0D8E4" }, line: { type: "none" }
  });
  y3 += 0.07;

  // CLINICAL NOTES
  slide.addShape(pres.shapes.RECTANGLE, {
    x: col3x + padding, y: y3, w: cW - 2*padding, h: SEC_LABEL_H,
    fill: { color: col }, line: { type: "none" }
  });
  slide.addText("📋 CLINICAL NOTES", {
    x: col3x + padding, y: y3, w: cW - 2*padding, h: SEC_LABEL_H,
    fontSize: SEC_LABEL_FS, fontFace: "Arial", bold: true,
    color: C.white, margin: 3
  });
  y3 += SEC_LABEL_H + 0.06;
  const notesH = rowTop + rowH - y3 - 0.12;
  slide.addText(drug.notes, {
    x: col3x + padding, y: y3, w: cW - 2*padding, h: notesH,
    fontSize: SEC_BODY_FS - 0.5, fontFace: "Arial",
    color: C.textDark, margin: 0, wrap: true
  });

  // ---- FOOTER ----
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: H - 0.22, w: W, h: 0.22,
    fill: { color: C.navy }, line: { type: "none" }
  });
  slide.addText(`Emergency Drugs Reference  •  ${drug.name}  •  For Clinical Use Only  •  Verify doses with current formulary`, {
    x: 0.2, y: H - 0.22, w: W - 0.4, h: 0.22,
    fontSize: 7, fontFace: "Arial",
    color: C.gray, align: "center", margin: 0
  });
}

// ============================================================
// BUILD PRESENTATION
// ============================================================
addCoverSlide(pres);
drugs.forEach(drug => addDrugSlide(pres, drug));

const outPath = "/home/daytona/workspace/emergency-drugs-poster/Emergency_Drugs_Poster_Chart.pptx";
pres.writeFile({ fileName: outPath }).then(() => {
  console.log("SUCCESS: " + outPath);
}).catch(err => {
  console.error("ERROR:", err);
  process.exit(1);
});